Treatment of acute myelogenous leukemia in children and adults.
Treatment of acute myelogenous leukemia in children and adults.
复制标题
治疗儿童和成人急性髓性白血病。
DOI：
10.1056/nejm198008283030901
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
E. Frei
中科院分区：
文献类型：
--
作者：
H. Weinstein;R. Mayer;D. Rosenthal;B. Camitta;F. Coral;D. Nathan;E. Frei
我们设计了一个方案来解决急性髓性白血病完全缓解后复发的问题。缓解期患者接受14个月的治疗，包括早期和晚期强化化疗、序贯联合用药和高剂量阿糖胞苷持续输注。从1976年2月至1979年10月，83例50岁以下的连续患者入组本研究。完全缓解率为70%，Kaplan-Meier分析预测49 +/-17%的患者（平均+/- 2 S.D.）进入完全缓解期的患者将在两年内保持无病状态。0至17岁和18至50岁年龄组患者的完全缓解持续时间相当。
We designed a protocol to address the problem of relapse from complete remission in acute myelogenous leukemia. Patients in remission were treated for 14 months; early and later intensification of chemotherapy, sequential drug combinations, and high-dose continuous infusions of cytarabine were included. Eighty-three consecutive patients under 50 years of age were entered into this study from February 1976 to October 1979. The rate of complete remission is 70 per cent. A Kaplan-Meier analysis predicts that 49 +/- 17 per cent of patients (mean +/- 2 S.D.) who entered complete remission will remain free of disease at two years. Durations of complete remission for patients in the 0 to 17-year and 18 to 50-year age groups are comparable.